466 related articles for article (PubMed ID: 21612550)
1. Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.
Valenzano KJ; Khanna R; Powe AC; Boyd R; Lee G; Flanagan JJ; Benjamin ER
Assay Drug Dev Technol; 2011 Jun; 9(3):213-35. PubMed ID: 21612550
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological chaperones as therapeutics for lysosomal storage diseases.
Boyd RE; Lee G; Rybczynski P; Benjamin ER; Khanna R; Wustman BA; Valenzano KJ
J Med Chem; 2013 Apr; 56(7):2705-25. PubMed ID: 23363020
[TBL] [Abstract][Full Text] [Related]
3. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
Thomas R; Kermode AR
Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
[TBL] [Abstract][Full Text] [Related]
4. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.
Sánchez-Fernández EM; García Fernández JM; Mellet CO
Chem Commun (Camb); 2016 Apr; 52(32):5497-515. PubMed ID: 27043200
[TBL] [Abstract][Full Text] [Related]
5. Personalized Pharmacoperones for Lysosomal Storage Disorder: Approach for Next-Generation Treatment.
Haneef SA; Doss CG
Adv Protein Chem Struct Biol; 2016; 102():225-65. PubMed ID: 26827607
[TBL] [Abstract][Full Text] [Related]
6. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.
Parenti G
EMBO Mol Med; 2009 Aug; 1(5):268-79. PubMed ID: 20049730
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders.
Parenti G; Andria G; Valenzano KJ
Mol Ther; 2015 Jul; 23(7):1138-1148. PubMed ID: 25881001
[TBL] [Abstract][Full Text] [Related]
8. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity.
Fan JQ
Biol Chem; 2008 Jan; 389(1):1-11. PubMed ID: 18095864
[TBL] [Abstract][Full Text] [Related]
9. A chaperone-mediated approach to enzyme enhancement as a therapeutic option for the lysosomal storage disorders.
Pastores GM; Sathe S
Drugs R D; 2006; 7(6):339-48. PubMed ID: 17073517
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological chaperones for enzyme enhancement therapy in genetic diseases.
Aymami J; Barril X; Rodríguez-Pascau L; Martinell M
Pharm Pat Anal; 2013 Jan; 2(1):109-24. PubMed ID: 24236974
[TBL] [Abstract][Full Text] [Related]
11. Recent developments in therapeutic approaches for lysosomal storage diseases.
Urbanelli L; Magini A; Polchi A; Polidoro M; Emiliani C
Recent Pat CNS Drug Discov; 2011 Jan; 6(1):1-19. PubMed ID: 21073432
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoperone drugs: targeting misfolded proteins causing lysosomal storage-, ion channels-, and G protein-coupled receptors-associated conformational disorders.
Hou ZS; Ulloa-Aguirre A; Tao YX
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):611-624. PubMed ID: 29851355
[TBL] [Abstract][Full Text] [Related]
13. Treatment of lysosomal storage diseases: recent patents and future strategies.
Ortolano S; Viéitez I; Navarro C; Spuch C
Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):9-25. PubMed ID: 24433521
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical Chaperones and Proteostasis Regulators in the Therapy of Lysosomal Storage Disorders: Current Perspective and Future Promises.
Mohamed FE; Al-Gazali L; Al-Jasmi F; Ali BR
Front Pharmacol; 2017; 8():448. PubMed ID: 28736525
[TBL] [Abstract][Full Text] [Related]
15. Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses.
Losada Díaz JC; Cepeda Del Castillo J; Rodriguez-López EA; Alméciga-Díaz CJ
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905715
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic strategies to ameliorate lysosomal storage disorders--a focus on Gaucher disease.
Sawkar AR; D'Haeze W; Kelly JW
Cell Mol Life Sci; 2006 May; 63(10):1179-92. PubMed ID: 16568247
[TBL] [Abstract][Full Text] [Related]
17. Treatment options for lysosomal storage disorders: developing insights.
van Gelder CM; Vollebregt AA; Plug I; van der Ploeg AT; Reuser AJ
Expert Opin Pharmacother; 2012 Nov; 13(16):2281-99. PubMed ID: 23009070
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological Chaperones: Beyond Conformational Disorders.
Leidenheimer NJ
Handb Exp Pharmacol; 2018; 245():135-153. PubMed ID: 29071508
[TBL] [Abstract][Full Text] [Related]
19. Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis.
Mu TW; Fowler DM; Kelly JW
PLoS Biol; 2008 Feb; 6(2):e26. PubMed ID: 18254660
[TBL] [Abstract][Full Text] [Related]
20. ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones.
Wei H; Kim SJ; Zhang Z; Tsai PC; Wisniewski KE; Mukherjee AB
Hum Mol Genet; 2008 Feb; 17(4):469-77. PubMed ID: 17989065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
